En nedsat følsomhed på > 10 gange over for tipranavir er usædvanlig (< 2, 5% af de testede isolater) i vira fra patienter, der er behandlet med flere regimer, indeholdende adskillige peptidiske proteasehæmmere.
Greater than 10-fold resistance to tipranavir is uncommon (< 2.5% of tested isolates) in viruses obtained from highly treatment experienced patients who have received multiple peptidic protease inhibitors.